Premium
Bionanoparticle‐Based Delivery in Antihypertensive Vaccine Mediates DC Activation through Lipid‐Raft Reorganization
Author(s) -
Hu Xiajun,
Chen Xiao,
Shi Xiaoli,
Gao Jingwei,
Ao Zhuo,
Li Nan,
Yuan Jinghe,
Fang Xiaohong,
Qiu Zhihua,
Zhou Zihua,
Liao Yuhua,
Han Dong
Publication year - 2020
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202000346
Subject(s) - lipid raft , raft , membrane , immunogenicity , biophysics , microbiology and biotechnology , signal transduction , materials science , membrane curvature , proto oncogene tyrosine protein kinase src , chemistry , lipid bilayer , antigen , biology , biochemistry , immunology , copolymer , composite material , polymer
Bionanoparticles (BNPs) are widely used as vaccine carriers. Compared with classic protein carriers, BNPs exhibit nanostructures that enable them to interaction with biointerface‐like cell membrane or membrane domains. An antihypertensive vaccine ATR‐NP is produced based on a virus‐like particle (VLP) Qβ carrier. Qβ shows great delivery efficiency and immunogenicity to antigen‐presenting cells (APCs) such as dendritic cells (DCs), and DC activation induced by ATR‐NP is highly dependent on membrane lipid rafts. Further studies reveal that ATR‐NP exhibits tight affinity to rafts, and interface effects between them prompt membrane phase separation and raft accumulation through NP‐induced membrane curvature change. Lipid rafts are accumulated and expanded together with a decline of their diffusion in membrane, which benefits signaling protein Src partition in rafts. The heterogeneous protein partition implies functional centralization for stronger signal transduction. In conclusion, targeting and reorganizing membrane domains such as lipid rafts suggests BNPs could be used as vaccine carriers and is a potent strategy for vaccine and other immunological agent design.